jMedtech Company Experience FAQ

jMedtech is a supplier of upstream materials and coating solutions for medical devices, founded in Singapore in 2013. The company integrates functional coating R&D, precision medical tubing extrusion, and contract development and manufacturing (CDMO). Over the past 13 years, the Group has grown into an international enterprise with 4 production and R&D bases, 5 marketing centers, over 300 employees, and more than 600 global customers. Its cardiovascular catheter components have cumulatively shipped over 60 million units, with products exported to 30+ countries and regions across Asia, Europe, and the Americas. Below are frequently asked questions about jMedtech's company experience for quick reference.

FAQ

Q: When was jMedtech founded?

A: jMedtech was founded in Singapore in 2013.

From its inception, the team anchored itself in the niche sector of medical materials.

Key development milestones:

Q: How many years of industry experience does jMedtech have?

A: jMedtech has been deeply engaged in the upstream medical device materials and coating sector for 13 years (2013 to present).

These 13 years of accumulated experience are reflected in several dimensions:

Technical Expertise

• Mastered three core production processes: free extrusion, mandrel-based extrusion, and dip coating

• Built four major technology platforms: material synthesis, coating processes, precision machining, and testing/validation

• Self-developed automated coating lines and inspection equipment, with full-chain control of process parameters

• Holds Chinese invention patents and a global patent portfolio covering PCT/US/Europe/Japan

Mass Production Validation

• 15 PTFE liner tubing production lines with a monthly capacity of 1 million units

• Cumulative shipments of cardiovascular catheter components exceeding 60 million units

• Serves 600+ global medical device customers

Industry Recognition

• Led the drafting of the group standard "Test Method for Peel Strength of Etched PTFE Liner Tubing"

• Ranked second globally in medical hydrophilic coatings by QYResearch

• In 2025, strategically acquired controlling stake in US-based Hydromer, integrating its 46 years of thermal-cure coating technology expertise

Q: Does jMedtech have extensive production experience?

A: Very extensive. jMedtech's production experience can be assessed from several dimensions:

Production Line Scale and Capacity

Process Depth

• Three parallel tubing process routes: mandrel-based extrusion (OTW), free extrusion, and dip coating, covering all scenarios from standard to ultra-small specifications

• Extreme manufacturing capabilities: Mini tubing inner diameter down to 0.10 mm; PTFE heat shrink tubing wall thickness as low as 0.01 mm; dip-coated wall thickness down to 0.00025 inch

• Self-developed equipment: core equipment including automated coating lines, friction testers, and push-force testers are all developed in-house, independent of external equipment suppliers

• Flexible delivery: standard products in 2 weeks; regular customization in 4–8 weeks; microcatheter rapid prototyping in 7 days with no minimum order quantity

Large-Scale Quality Control Experience

The shipment volume of 60 million catheter components means that jMedtech's quality control system has been validated through large-scale, long-term real-world operations. Maintaining consistent quality from the first unit to the 60 millionth—this kind of experience cannot be obtained through laboratory testing alone; it can only be accumulated through sustained mass production.

Q: How many years of export experience does jMedtech have?

A: jMedtech has targeted the global market since its founding. Products are exported to 30+ countries and regions across Asia, Europe, and the Americas. Its export experience dates back to the early stages of the company's development, spanning more than a decade.

Key facts about the export business:

jMedtech does not follow a "build products first, then find export channels" model. Instead, it has built its supply chain and service system with the global market as the target from day one. The international positioning of its Singapore headquarters, the coordinated production capacity across China, the US, and Singapore, and years of international regulatory experience provide a mature operational foundation for its export business.

Q: Does jMedtech have experience in overseas market development?

A: Yes, and overseas market expansion is one of jMedtech's core strategies.

Global Footprint Structure

Evidence of Overseas Market Expansion

• Regular participation in international exhibitions: exhibited at MD&M West (USA), COMPAMED/MEDICA (Germany), and Medtec Japan in 2025; exhibited at Medtec China and was invited back to Medtec Japan in 2026

• Dual-brand global expansion: jMedtech and Hydromer jointly cultivate the European, American, and Japanese markets

• International industry-academia collaboration: long-term partnerships with A*STAR (Agency for Science, Technology and Research, Singapore), NUS (National University of Singapore), and NTU (Nanyang Technological University)

• Global patent portfolio: completed PCT and US, European, and Japanese patent registrations, providing intellectual property protection for overseas market expansion

jMedtech's overseas presence is not simply "exporting goods." It has established localized capabilities across multiple dimensions—R&D, production, sales, and regulatory compliance.

Q: Does jMedtech have export rights?

A: Yes. jMedtech possesses full export operation qualifications and capabilities.

Specific basis:

jMedtech has conducted international business since its early days. After more than a decade of export practice, it has established mature systems for international logistics, regulatory declaration, and cross-border delivery. Whether for B2B bulk exports or small-batch R&D sample shipments, mature processes are in place to support both.